Comparative Pharmacology
Head-to-head clinical analysis: ISMO versus NITRO DUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISMO versus NITRO DUR.
ISMO vs NITRO-DUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide mononitrate is a nitrate that dilates coronary arteries and peripheral veins. It acts by releasing nitric oxide, which activates guanylate cyclase, increasing cGMP levels, leading to smooth muscle relaxation and vasodilation.
Nitroglycerin is a prodrug that is converted to nitric oxide (NO) in vascular smooth muscle, activating guanylyl cyclase, increasing cGMP, leading to vasodilation primarily in veins and arteries.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to minimize nitrate tolerance.
Transdermal: Initial 0.2-0.4 mg/h applied once daily, titrate to 0.4-0.8 mg/h; maximum 0.8 mg/h. Remove for 10-12 hours daily to prevent tolerance.
None Documented
None Documented
Clinical Note
moderateVismodegib + Digoxin
"Vismodegib may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateVismodegib + Digitoxin
"Vismodegib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateVismodegib + Deslanoside
"Vismodegib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateVismodegib + Acetyldigitoxin
"Vismodegib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 5-6 hours. In elderly patients or those with hepatic impairment, half-life may be prolonged (up to 8-10 hours), warranting dose adjustment.
2–3 minutes (nitroglycerin); prolonged to ~30 minutes for active metabolites. Clinical context: Requires frequent dosing or continuous administration for sustained effect.
Primarily renal; 80-90% of the dose is excreted as inactive metabolites (isosorbide mononitrate and isosorbide dinitrate) in urine. Less than 1% is excreted unchanged. Fecal excretion is minimal.
Primarily renal (>80% as inactive metabolites; <1% unchanged nitroglycerin). Minor biliary/fecal elimination.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator